Evidence map›Paper›PMID 38629365›Full record

ArticleRecent patents on anti-cancer drug discovery2025

Eukaryotic Initiation Factor 3C Can Affect the Proliferation and Invasion of Ovarian Cancer by Regulating the p53 Signalling Pathway.

Jingkaiwen Zhang, Hanlin Yang, Fang Wen, Qing Li, Hao Luo, Dan Zi

Abstract read
PubMed Publisher
In one paragraph

Article in Recent patents on anti-cancer drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jingkaiwen ZhangDepartment of Gynaecology and Obstetrics, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China.
Hanlin YangDepartment of Gynaecology and Obstetrics, Guizhou Provincial People's Hospital, Guiyang, 550002, China.
Fang WenDepartment of Gynaecology and Obstetrics, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China.
Qing LiCollege of Bioengineering, Key Lab of Biorheological Science and Technology, Ministry of Education, Chongqing University, Chongqing, 400030, China.
Hao LuoCollege of Bioengineering, Key Lab of Biorheological Science and Technology, Ministry of Education, Chongqing University, Chongqing, 400030, China.
Dan ZiDepartment of Gynaecology and Obstetrics, Guizhou Provincial People's Hospital, Guiyang, 550002, China.ORCID 0000-0002-0778-9003
Guiyang Medical University · CNChongqing University · CNGuizhou Provincial People's Hospital · CN

Funding

Doctoral Fund of Guizhou Provincial People's Hospital GZSYBA[2021]01Science and Technology Fund of Guizhou Province ZK[2022]270, ZK[2021]459
6 · The paper itself

Abstract

backgroundEukaryotic Initiation Factor 3C (EIF3C) represents a pivotal translational initiation factor in eukaryotes and has been shown to facilitate the progression of various neoplasms. However, its mechanistic role in ovarian cancer remains elusive.

methodsIn this research, the expression of EIF3C in ovarian cancer tissues was investigated using immunohistochemistry. In addition, the assessments were made on changes in cellular proliferation, invasion, and apoptotic abilities by reducing the expression of EIF3C in ovarian cancer cells. By utilizing microarray analysis, a comparison was performed between the downregulated EIF3C group and the control group of ovarian cancer cells, revealing the genes that were expressed differently. Furthermore, the signalling pathways associated with cellular proliferation were validated. The functional role of EIF3C in vivo was investigated using a xenograft tumour model.

resultsThe immunohistochemical analysis showed that elevated levels of EIF3C are linked to a negative prognosis in patients with ovarian cancer. Suppression of EIF3C greatly hindered the growth and spread of SK-OV-3 and HO-8910 cells while enhancing cellular programmed cell death. Following KEGG and GSEA enrichment analyses of differentially expressed genes, the p53 signalling pathway was found to be associated with EIF3C. Suppression of EIF3C resulted in the upregulation of the p53 signalling pathway, leading to the inhibition of cell proliferation and invasion and the promotion of apoptosis.

conclusionThere is a correlation between overexpression of EIF3C in tumour tissues of ovarian cancer patients and this is associated with a poorer prognosis. By influencing the p53 signaling pathway, EIF3C facilitates the growth and infiltration of cells in ovarian cancer.

Indexed as

Eukaryotic Initiation Factor-3Ovarian NeoplasmsTumor Suppressor Protein p53AnimalsApoptosisCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceMice, Inbred BALB CMice, NudeMiddle AgedNeoplasm InvasivenessSignal TransductionEIF3C protein, humanEukaryotic Initiation Factor-3TP53 protein, humanTumor Suppressor Protein p53Eukaryotic initiation factor 3Cgynecological cancers.invasiononcologyovarian cancerp53 signalling pathwayproliferation

Identifiers

PMID38629365
OpenAlexW4394874233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.